PMID- 18069633
OWN - NLM
STAT- MEDLINE
DCOM- 20100202
LR  - 20071211
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 29
IP  - 7
DP  - 2007 Jul
TI  - [Relationship between serum VEGF level and VEGF, COX-2 and MVD expression in 
      breast cancer tissues].
PG  - 522-5
AB  - OBJECTIVE: To investigate the relationship between serum VEGF (sVEGF) level and 
      VEGF, COX-2 and MVD expression in breast cancer, and to discuss their role in 
      angiogensis of breast cancer. METHODS: sVEGF level was detected by ELISA in 68 
      preoperative breast cancer, 35 benign breast disease and 20 healthy women. The 
      expression of VEGF, COX-2 and MVD was detected by immunohistochemical method in 
      tissues of breast cancer and breast benign diseases, and to analyze the 
      relationship of sVEGF, VEGF, COX-2 and MVD. RESULTS: (1) sVEGF level in 
      preoperative breast cancers was 306.51 pg/ml (interquartile range from 190.44 to 
      442.04 pg/ml), in benign diseases was 150.82 pg/ml (interquartile range from 
      82.36 to 212.34 pg/ml), and in healthy control was 105.93 pg/ml (interquartile 
      range from 78.54 to 157.77 pg/ml). The sVEGF level of preoperative breast cancer 
      group was significantly higher than that of breast benign disease group and 
      healthy women (P = 0.001). (2) The VEGF expression positive rate in breast cancer 
      (67.65%) was significantly higher than that in breast benign disease (44.12%) (P 
      = 0.015). The COX-2 expression positive rate in breast cancer (42.86%) was 
      significantly higher than that in breast benign disease (11.43%) (P = 0.002). (3) 
      the COX-2 expression positive rate in sVEGF high level patients (56.00%) was 
      significantly higher than that in sVEGF normal level patients (11.11%) (P = 
      0.024), and MVD in sVEGF high level patients (27.32 +/- 3.40) was also higher 
      than that in sVEGF normal level patients (15.31 +/- 6.16) (P = 0.011). (4) The 
      sVEGF level (322.09 +/- 79.31) of 68 breast cancer patients whose VEGF was 
      positive in breast cancer tissues was significantly higher than that in VEGF 
      negative group (222.47 +/- 73.53) (P = 0.017). (5) The COX-2 expression positive 
      rate in VEGF positive expression group (65.21%) was significantly higher than 
      that in VEGF negative expression group (18.18%) (P = 0.017). The MVD expression 
      in COX-2 positive expression group (22.94 +/- 5.51) was significantly higher than 
      that in COX-2 negative expression group (10.30 +/- 4.42) (P = 0.027). CONCLUSION: 
      sVEGF level in breast cancer is significantly higher than that in breast benign 
      disease and healthy women, and is correlated with the expression of COX-2 and MVD 
      in breast cancer tissues.
FAU - Li, En-xiao
AU  - Li EX
AD  - Cancer Center of First Affiliated Hospital of Medical College, Xi'an Jiaotong 
      University, Xi'an 710061, China. doclienxiao@sina.com
FAU - Wu, Yin-ying
AU  - Wu YY
FAU - Shi, Fan
AU  - Shi F
FAU - Wu, Yuan
AU  - Wu Y
FAU - Guo, Jun-jun
AU  - Guo JJ
FAU - Dong, Dan-feng
AU  - Dong DF
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0 (Antigens, CD34)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, CD34/metabolism
MH  - Breast Neoplasms/blood/blood supply/*metabolism/pathology
MH  - Carcinoma, Ductal, Breast/blood/blood supply/*metabolism/pathology
MH  - Cyclooxygenase 2/*metabolism
MH  - Female
MH  - Fibroadenoma/blood/blood supply/metabolism
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Microvessels/*pathology
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neovascularization, Pathologic
MH  - Prognosis
MH  - Vascular Endothelial Growth Factor A/blood/*metabolism
EDAT- 2007/12/12 09:00
MHDA- 2010/02/03 06:00
CRDT- 2007/12/12 09:00
PHST- 2007/12/12 09:00 [pubmed]
PHST- 2010/02/03 06:00 [medline]
PHST- 2007/12/12 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2007 Jul;29(7):522-5.